Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNS NASDAQ:ESTA NASDAQ:INGN NASDAQ:RTIX NASDAQ:SIEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAVANOS MEDICAL$11.25-3.4%$12.32$11.21▼$25.36$538.28M1.12392,004 shs450,766 shsESTAEstablishment Labs$41.57-2.1%$39.19$26.56▼$50.85$1.23B0.8475,070 shs264,079 shsINGNInogen$6.35-4.9%$6.64$5.70▼$13.33$179.61M1.66243,215 shs175,607 shsRTIXRTI Surgical$3.14$3.14$1.46▼$5.40$234.25M2.14622,541 shs686,036 shsSIENSientra$0.43$0.16▼$4.94$2.08M2.044.15 million shs3.44 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAVANOS MEDICAL+1.69%-4.87%-3.93%-6.05%-48.55%ESTAEstablishment Labs-2.77%-7.66%+13.47%+34.98%-10.67%INGNInogen+2.14%-8.62%+3.09%-2.05%-30.56%RTIXRTI Surgical0.00%0.00%0.00%0.00%0.00%SIENSientra0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAVANOS MEDICAL2.893 of 5 stars0.05.00.00.01.91.72.5ESTAEstablishment Labs2.1968 of 5 stars3.41.00.00.02.12.50.6INGNInogen4.2572 of 5 stars3.34.00.03.91.41.71.3RTIXRTI SurgicalN/AN/AN/AN/AN/AN/AN/AN/ASIENSientraN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAVANOS MEDICAL 0.00N/AN/AN/AESTAEstablishment Labs 2.83Moderate Buy$54.8331.91% UpsideINGNInogen 2.50Moderate Buy$11.0073.23% UpsideRTIXRTI Surgical 0.00N/AN/AN/ASIENSientra 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INGN, AVNS, ESTA, RTIX, and SIEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025ESTAEstablishment LabsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $70.007/9/2025ESTAEstablishment LabsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $47.006/16/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/15/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/13/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.005/22/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy$12.005/16/2025ESTAEstablishment LabsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$62.005/14/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$48.005/8/2025INGNInogenStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $7.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAVANOS MEDICAL$687.80M0.76$11.48 per share0.98$18.03 per share0.62ESTAEstablishment Labs$166.02M7.24N/AN/A$1.90 per share21.88INGNInogen$335.70M0.51N/AN/A$7.30 per share0.87RTIXRTI Surgical$308.38M0.76$0.30 per share10.31$2.89 per share1.09SIENSientra$90.55M0.00N/AN/A($0.04) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAVANOS MEDICAL-$392.10M-$8.378.376.50N/A-55.80%6.26%4.63%7/30/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.100.00N/AN/A-52.34%-196.25%-26.64%8/5/2025 (Estimated)INGNInogen-$35.89M-$1.15N/AN/AN/A-8.08%-14.76%-9.01%8/5/2025 (Estimated)RTIXRTI Surgical-$211.64M-$0.16N/AN/AN/A-70.56%N/AN/AN/ASIENSientra-$73.31M-$5.57N/AN/AN/A-65.93%N/A-40.45%N/ALatest INGN, AVNS, ESTA, RTIX, and SIEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ESTAEstablishment Labs-$0.54N/AN/AN/A$50.80 millionN/A8/5/2025Q2 2025INGNInogen-$0.25N/AN/AN/A$90.40 millionN/A7/30/2025Q2 2025AVNSAVANOS MEDICAL$0.18N/AN/AN/A$165.50 millionN/A5/7/2025Q1 2025ESTAEstablishment Labs-$0.83-$0.70+$0.13-$0.70$41.15 million$41.38 million5/7/2025Q1 2025INGNInogen-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 million5/6/2025Q1 2025AVNSAVANOS MEDICAL$0.19$0.26+$0.07$0.14$161.75 million$167.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAVANOS MEDICALN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/ARTIXRTI SurgicalN/AN/AN/AN/AN/ASIENSientraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAVANOS MEDICAL0.122.571.56ESTAEstablishment Labs5.723.362.05INGNInogenN/A3.072.67RTIXRTI SurgicalN/AN/AN/ASIENSientraN/A0.570.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAVANOS MEDICAL95.17%ESTAEstablishment Labs72.91%INGNInogen89.94%RTIXRTI Surgical60.97%SIENSientra15.38%Insider OwnershipCompanyInsider OwnershipAVNSAVANOS MEDICAL2.64%ESTAEstablishment Labs11.09%INGNInogen1.46%RTIXRTI Surgical3.70%SIENSientra1.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAVANOS MEDICAL2,22746.24 million45.02 millionOptionableESTAEstablishment Labs1,01828.92 million25.71 millionOptionableINGNInogen1,03026.89 million26.49 millionOptionableRTIXRTI Surgical89174.60 millionN/AOptionableSIENSientra30411.96 million11.78 millionOptionableINGN, AVNS, ESTA, RTIX, and SIEN HeadlinesRecent News About These CompaniesNeuroPace Hires Former CFO of Staar SurgicalJune 24, 2025 | marketwatch.comSienna Resources Inc. Closes Private PlacementJune 17, 2025 | newsfilecorp.comNSpinning the State: Franklin, Sun Prairie, ClevelandMarch 12, 2025 | wtmj.comWFranklin-based Tiger Aesthetics invests $50M in Franklin manufacturing facilityMarch 7, 2025 | bizjournals.comIndonesia Medical Aesthetics Market Report 2024-2029 - 11.5% CAGR Forecast, with Market Set to Reach USD 495.64 Million by 2029November 6, 2024 | finance.yahoo.comGlobal Cosmetic Implants Market Set to Reach USD 1…November 4, 2024 | pharmiweb.comPGlobal Axillary Hyperhidrosis Treatment Market Projected to Reach USD 3.3 Billion by 2033 at a 6.7% of CAGROctober 29, 2024 | fmiblog.comFButtock Augmentation Market is expected to Grow USD 26.9 Billion by 2032 increase at a CAGR of around 27.4%October 22, 2024 | pharmiweb.comPCosmetic Surgery Market Size Projected to Reach USD 94.5 Billion by 2032 with a CAGR of 5.8% - SNS InsiderOctober 3, 2024 | finance.yahoo.comExtremity Tissue Expanders Market is projected to grow at a CAGR of 6.3% to reach USD 1.84 Billion by 2028October 2, 2024 | fmiblog.comFAesthetic Medicine Market Size to Worth USD 205.32 Billion by 2033August 26, 2024 | finance.yahoo.comGel Implants Market is projected to grow at a 3.8% CAGR and reach USD 1,760 Million by 2033 | FMI StudyAugust 7, 2024 | fmiblog.comFGlobal Cosmetology Market is anticipated to surpass USD 316.05 billion by the year 2033July 22, 2024 | pharmiweb.comPCosmetic Surgery Products Market Set to Reach USD 41.64 Billion by 2033 at a 8.1% of CAGRJuly 19, 2024 | pharmiweb.comPAesthetic Implants Market to Reach USD 10 Billion by 2032 | Market.usMay 29, 2024 | pharmiweb.comPAesthetic Medicine Market Forecast to Reach USD 571.6 Billion by 2033 | Market.usMay 29, 2024 | pharmiweb.comPBreast Implants Market, Projected to Expand at a 7.7% CAGR to 2033May 22, 2024 | pharmiweb.comPGlobal Breast Implant Market Projected to Reach US$ 4.1 Billion by 2032May 15, 2024 | finance.yahoo.comPace Industries in Grafton announces it will lay off 90 workers beginning in JuneMay 9, 2024 | msn.comGlobal Breast Reconstruction Surgery and Treatment Market Will Surge at a CAGR of 5.9% to Reach USD 1.61 Billion By 2033May 8, 2024 | fmiblog.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesChipotle: Too Spicy for Smart Money to Resist After Stock SplitBy Jeffrey Neal Johnson | July 11, 2025View Chipotle: Too Spicy for Smart Money to Resist After Stock SplitBuybacks Galore: Repurchases From the Oval Office to Olive GardenBy Leo Miller | June 30, 2025View Buybacks Galore: Repurchases From the Oval Office to Olive Garden3 Fast Food Stocks That Won’t Give You Indigestion Right NowBy Brian O'Connell | July 16, 2025View 3 Fast Food Stocks That Won’t Give You Indigestion Right NowWhy Prologis May Be the Smartest Backdoor Bet on AI Real EstateBy Chris Markoch | July 17, 2025View Why Prologis May Be the Smartest Backdoor Bet on AI Real EstateHow Texas Roadhouse Is Winning in a Changing Consumer MarketBy Dan Schmidt | July 14, 2025View How Texas Roadhouse Is Winning in a Changing Consumer MarketINGN, AVNS, ESTA, RTIX, and SIEN Company DescriptionsAVANOS MEDICAL NYSE:AVNS$11.25 -0.39 (-3.35%) Closing price 03:59 PM EasternExtended Trading$11.23 -0.02 (-0.18%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Establishment Labs NASDAQ:ESTA$41.57 -0.88 (-2.07%) Closing price 04:00 PM EasternExtended Trading$41.67 +0.10 (+0.24%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.Inogen NASDAQ:INGN$6.35 -0.33 (-4.94%) Closing price 04:00 PM EasternExtended Trading$6.42 +0.08 (+1.18%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.RTI Surgical NASDAQ:RTIXSurgalign Holdings, Inc. is a global medical technology company, which engages in designing, developing and manufacturing biologic metal and synthetic implants worldwide. It focuses on delivering spine solutions that drive clinical and economic outcomes. The company markets its products throughout the United States and other countries worldwide through an expanding network of independent distributors. The company was founded in February 1998 and is headquartered in Deerfield, IL.Sientra NASDAQ:SIENSientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides fat transfer systems; body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists, and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Irvine, California. On February 12, 2024, Sientra, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
